Q Therapeutics Announces Joint Venture With REPROCELL PARTNERSHIP WILL DEVELOP IPSC-DERIVED PRODUCTS TO TREAT CENTRAL NERVOUS SYSTEM DISEASES INVOLVING DEMYELINATION AND DEGENERATIONSALT LAKE CITY and YOKOHAMA, Japan, April 23, 2018 (GLOBE NEWSWIRE) --...

Remedy Pharmaceuticals Co-founder and CEO Brings Clinical Trial and Company-Building Experience to ReNetX Bio Advisory Board NEW HAVEN, Conn., Feb. 12, 2018 (GLOBE NEWSWIRE) -- Sven Jacobson will be the first to admit that developing a new therapeutic for spinal cord injury is a challenging road. But the latest member of...

Q Therapeutics Announces Research Collaboration With REPROCELL SALT LAKE CITY and YOKOHAMA, Japan, Dec. 13, 2017 (GLOBE NEWSWIRE) -- Q Therapeutics, Inc., a developer of clinical-stage cell therapies for central nervous system (CNS) disease and injury,...

ReNetX Bio Receives $7M Commitment from Wings for Life to Bring Spinal Cord Treatment to Trial NEW HAVEN, Conn., Nov. 07, 2017 (GLOBE NEWSWIRE) -- The Wings for Life foundation has made a significant commitment to ReNetX Bio, a New-Haven, Conn. based biotech startup that is advancing a...

Leading Spinal Cord Injury Experts Join ReNetX Scientific Advisory Board NEW HAVEN, Conn., Oct. 10, 2017 (GLOBE NEWSWIRE) -- ReNetX Bio, a company developing first-in-class therapeutics to treat injury to the central nervous system, is expanding its Scientific Advisory...